Hemoglobinopathies Market

Hemoglobinopathies Market Revenue to Reach USD 13,465.2 Million by 2026

Hemoglobinopathies market

Report findings titled “Hemoglobinopathies Market By Indication (Sickle Cell Disease, Alpha Thalassemia, Beta Thalassemia and Others), Therapy (Blood Transfusion, Iron Chelation Therapy, Bone Marrow Transplantation and Others), Diagnosis (Blood Tests, Genetic Tests, Diagnosis preimplantation genetics (PGD) and others) and end user (hospitals, diagnostic laboratories, clinics and other end The market is estimated to grow at a compound annual growth rate (CAGR) of over 10.34% and it will will reach over $13,465.2 million by 2026.

@https://www.fnfresearch.com/hemoglobinopathies-market-by-indication-sickle-cell-disease-alpha

Major key players operating in the market are

Alnylam Pharmaceuticals
bluebird bio inc.
Celgene Company
Emmaus Life Sciences Inc.
Gamide cell
Global Blood Therapeutics
Prolong Pharmaceuticals
let’s bleed
Therapeutics Inc. and Sanofi

Hemoglobinopathies are caused by both anemia and mutations in the patient’s genes. Default hemoglobin formation can occur under three different circumstances, including structural defects in the hemoglobin molecule, decreased production of one of the two subunits that make up the hemoglobin molecule, and interactions abnormalities between subunits that would normally be considered safe. There is a spectrum of severity when it comes to diseases. The most common diagnostic tools and tests for hemoglobinopathy and thalassemia are genetic diagnostics, genetic and blood tests, alkaline and acid gel electrophoresis, hemoglobin electrophoresis, prenatal genetic testing and chromatographic exchange of HbA2 ions.

@https://www.fnfresearch.com/sample/hemoglobinopathies-market-by-indication-sickle-cell-disease-alpha

The improvement in R&D investments should contribute to the development of demand for new therapies. The National Heart, Lung, and Blood Institute (NHLBI), part of the National Health Institutes (NIH), funds SCD research programs to find new ways to identify and manage the disease and improve outcomes for patients. New techniques are being developed using advances in gene editing technology to modify or delete the faulty sickle cell gene and bring the restored gene back to patients. Support for sickle cell disease prevention and care through laws such as the Sickle Cell Research, Surveillance, Prevention and Care Act 2018 should also lead to better management of the situation.

The hemoglobinopathies market is segmented into indication, therapy, diagnostics, end user and regional segment. The indications segment is segmented into sickle cell disease, alpha-thalassemia, beta-thalassemia and others. Therapeutic segment is divided into iron chelation therapy, blood transfusion, bone marrow transplant and others. In 2018, transfusion therapy held the largest market share. The increase in policy measures to increase the number of blood donors is a high-impact driver for the demand for hemoglobinopathies.

@https://www.fnfresearch.com/inquiry/hemoglobinopathies-market-by-indication-sickle-cell-disease-alpha

The Diagnosis segment is divided into blood tests, genetic tests, preimplantation genetic diagnosis (PGD) and others. In 2018, blood tests led the diagnostics segment in terms of revenue. The fact that blood tests are widely used as a frontline screening tool is a major contributor to its large market share. Due to its efficiency in accurate diagnosis and monitoring, genetic testing for diagnosis of sickle cell disease is expected to be the fastest growing segment during the forecast period. The end user segment is segmented into hospitals, diagnostic laboratories, clinics and other end users.

? @https://www.fnfresearch.com/customization/hemoglobinopathies-market-by-indication-sickle-cell-disease-alpha

This report segments the global hemoglobinopathies market as follows:

Global Hemoglobinopathies Market: Indication Segment Analysis

sickle cell disease
Alpha Thalassemia
Beta Thalassemia
Others

Global Hemoglobinopathies Market: Therapeutic Segment Analysis

Blood transfusion
Iron chelation therapy
Bone marrow transplant
Others

Global Hemoglobinopathies Market: Diagnostics Segment Analysis

Blood test
Genetic test
Preimplantation Genetic Diagnosis (PGD)
Other

Global Hemoglobinopathies Market: End User Segment Analysis

Hospitals
Diagnostic laboratories
Clinics
Other end use

Global Hemoglobinopathies Market: Regional Segmentation Analysis

North America
United States
Canada
Europe
Germany
Great Britain
France
Spain
Italy
The rest of Europe
Asia Pacific
China
Japan
India
South Korea
South East Asia
Rest of Asia-Pacific
Latin America
Brazil
Mexico
Rest of Latin America
Middle East and Africa
GCC
South Africa
Rest of the Middle East and Africa

@https://www.fnfresearch.com/buynow/su/hemoglobinopathies-market-by-indication-sickle-cell-disease-alpha

Facts and factors
At 2108, Sargame,
Nanded City,
sinhagad road,
Pune 411041, India
USA: +1-347-989-3985
Email: sales@fnfresearch.com
The Web: https://www.fnfresearch.com

Facts & Factors is a leading market research organization offering industry expertise and scrupulous consulting services to clients for their business development. The reports and services offered by Facts and Factors are used by prestigious academic institutions, start-ups and companies around the world to measure and understand changing international and regional business environments. The conviction of our clients/customers in our solutions and services has driven us to always offer the best. Our advanced search solutions have helped them make appropriate decisions and guide their business expansion strategies.

This press release was published on openPR.

#Hemoglobinopathies #Market #Revenue #Reach #USD #Million

Leave a Comment

Your email address will not be published. Required fields are marked *